

# AddiCAD

FIELD TESTING OF ADDICAD:  
AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD



FACT SHEET

**ADDICAD** The logo consists of the word 'ADDICAD' in a bold, sans-serif font, followed by a stylized yellow 'ab' with a small white cross symbol to its right.

**ACRONYM**

AddiCAD

**FULL TITLE**

Field testing of AddiCAD:

An innovation diagnostic test for tuberculosis that adds to CAD

**PROGRAMME**

EDCTP3

**CONTRACT NUMBER**

Grant Agreement N° 101248855

**ABSTRACT**

The overall goal of AddiCAD is to fill a critical gap in tuberculosis diagnosis in high-burden, resource-limited settings. Tuberculosis remains the leading cause of infectious disease-related deaths worldwide, with undiagnosed and late-stage cases contributing to continued transmission and poor treatment outcomes. Despite advancements in TB diagnostics, existing tests are often too costly, too complex, or insufficiently accessible. There is an urgent need for a rapid, affordable, non-sputum-based diagnostic tool at point of care.

AddiCAD will develop a novel diagnostic solution that combines AI chest X-ray analysis (CAD4TB) with a fingerstick-based biomarker test. By integrating CAD4TB scores with 3P-TB, a three-marker host protein biosignature test measuring SAA-1, CRP and IP-10, AddiCAD aims to enhance diagnostic accuracy beyond current standalone methods. Preliminary results demonstrated exceptional performance.

To bring this innovation to scale, AddiCAD brings together strong African and European partners with clinical, diagnostic, data science, regulatory and commercialisation expertise.

**Together, the consortium aims to:**

- Develop and optimize an aptamer-based point-of-care sensor for the 3P-TB signature.
- Integrate CAD4TB scores, 3P-TB biomarker results and BMI into the AddiCAD diagnostic model.
- Validate AddiCAD in 1,000 adults with presumptive TB in South Africa, The Gambia and Namibia.
- Engage regulatory, scientific and commercial stakeholders to support adoption and integration into healthcare systems.

Through these activities, AddiCAD will deliver rapid, accurate and accessible point-of-care TB diagnosis and has the potential to fill a critical gap in improved TB detection in high-burden, resource-limited settings.

**DURATION**

36 months (01/05/2026 – 30/04/2029)

**PROJECT FUNDING**

2,508,155 EUR

**COORDINATOR**

Prof Stephanus Malherbe  
Stellenbosch University  
Email: malherbe@sun.ac.za

**CONSORTIUM**

- Delft Imaging Systems (the Netherlands)
- LifeSADX (South Africa)
- LINQ management GmbH (Germany)
- The London School of Hygiene and Tropical Medicine (UK, The Gambia)
- Stellenbosch University (South Africa)
- University of Namibia

**PROJECT MANAGEMENT**

Dr Christoph Cyranski  
LINQ management GmbH  
Email: c.cyranski@linq-management.com

**PROJECT WEBSITE**

[www.addicad.org](http://www.addicad.org)